Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale
- 11 marketed drugs
- 2nd largest oncology out-licensor globally
- 150+ active licenses
- 160+ new drugs into early-phase clinical trials
- $647 million revenue from royalties & IP
- $2.8 billion raised by their spinout and startup portfolio
![](https://predictive-oncology.com/wp-content/uploads/2023/03/crh_infographic-1024x1024.jpg)